Lucid Financial Statements From 2010 to 2026

LUCD Stock

USD 1.13 0.08 6.61%

Lucid Diagnostics' financial statements offer valuable quarterly and annual insights to potential investors, highlighting the company's current and historical financial position, overall management performance, and changes in financial standing over time. Key fundamentals influencing Lucid Diagnostics' valuation are provided below:

Gross Profit

-2.6 M

Market Capitalization

158.6 M

Enterprise Value Revenue

43.3194

Revenue

4.4 M

Earnings Share

(0.77)

There are over one hundred nineteen available fundamental ratios for Lucid Diagnostics, which can be analyzed over time and compared to other ratios. Investors should ensure to check all of Lucid Diagnostics' last-minute performance against the performance from 2010 to 2026 to make sure the company is sustainable down the road.

Lucid Diagnostics Total Revenue

5.25 Million

Check Lucid Diagnostics financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Lucid Diagnostics' main balance sheet or income statement drivers, such as Depreciation And Amortization of 997.8 K, Interest Expense of 28.4 K or Selling General Administrative of 24.3 B, as well as many indicators such as Price To Sales Ratio of 10.4, Dividend Yield of 0.0 or PTB Ratio of 7.25. Lucid financial statements analysis is a perfect complement when working with Lucid Diagnostics Valuation or Volatility modules.

Build AI portfolio with Lucid Stock

Check out the analysis of Lucid Diagnostics Correlation against competitors.

For information on how to trade Lucid Stock refer to our How to Trade Lucid Stock guide.

Lucid Diagnostics Balance Sheet

Trends

Current Value

Last Year

Historical Average

10 Year Trend

Total Assets

24 M

35.3 M

12.5 M

Slightly volatile

Other Current Liabilities

3.1 M

3.3 M

3.2 M

Slightly volatile

Total Current Liabilities

13.9 M

27.1 M

8.1 M

Slightly volatile

Other Liabilities

288.3 K

324.4 K

354.1 K

Slightly volatile

Accounts Payable

1.3 M

1.4 M

882 K

Slightly volatile

Cash

18.5 M

25.7 M

9.5 M

Slightly volatile

Cash And Short Term Investments

18.5 M

25.7 M

9.5 M

Slightly volatile

Common Stock Shares Outstanding

43.3 M

58.1 M

39.6 M

Slightly volatile

Liabilities And Stockholders Equity

24 M

35.3 M

12.5 M

Slightly volatile

Other Stockholder Equity

186.8 M

177.9 M

51 M

Slightly volatile

Total Liabilities

30.6 M

29.1 M

9.4 M

Slightly volatile

Total Current Assets

20.5 M

28.9 M

10.6 M

Slightly volatile

Common Stock

76.1 K

72.5 K

26.3 K

Slightly volatile

Non Current Assets Total

4 M

6.4 M

2.2 M

Slightly volatile

Non Currrent Assets Other

1 M

1.3 M

799.5 K

Slightly volatile

Short Term Investments

1.6 M

1.5 M

561.5 K

Slightly volatile

Non Current Liabilities Total

984.4 K

1.6 M

1 M

Slightly volatile

Other Current Assets

1.9 M

2.4 M

981.8 K

Slightly volatile

Capital Stock

65.8 M

62.7 M

11.9 M

Slightly volatile

Net Receivables

489 K

465.8 K

95.4 K

Slightly volatile

Property Plant Equipment

1.4 M

1.8 M

1.2 M

Slightly volatile

Short and Long Term Debt Total

14.1 M

24.4 M

5.9 M

Slightly volatile

Common Stock Total Equity

32.8 K

36.9 K

40.3 K

Slightly volatile

Capital Surpluse

96.9 M

109 M

118.9 M

Slightly volatile

Non Current Liabilities Other

829.6 K

933.3 K

1 M

Slightly volatile

Short Term Debt

13 M

22.4 M

4.8 M

Slightly volatile

Intangible Assets

629.3 K

662.4 K

2.8 M

Slightly volatile

Current Deferred Revenue

748.8 K

842.4 K

919.5 K

Slightly volatile

Short and Long Term Debt

17.9 M

21.4 M

14.9 M

Slightly volatile

Good Will

588.2 M

661.7 M

722.3 M

Slightly volatile

Lucid Diagnostics Income Statement

Trends

Current Value

Last Year

Historical Average

10 Year Trend

Depreciation And Amortization

997.8 K

1.1 M

2.1 M

Very volatile

Selling General Administrative

24.3 B

23.2 B

4 B

Slightly volatile

Selling And Marketing Expenses

19.9 B

18.9 B

3.3 B

Slightly volatile

Other Operating Expenses

31.5 M

58 M

17.8 M

Slightly volatile

Research Development

6.9 M

3.7 M

Slightly volatile

Total Operating Expenses

28.1 M

48.5 M

15.5 M

Slightly volatile

Interest Income

305.8 K

370.3 K

150.9 K

Slightly volatile

Lucid Diagnostics Cash Flow Statement

Trends

Current Value

Last Year

Historical Average

10 Year Trend

Stock Based Compensation

5.7 M

5.2 M

2.8 M

Slightly volatile

Depreciation

882.8 K

1.3 M

463.2 K

Slightly volatile

Capital Expenditures

498.4 K

581.4 K

725.7 K

Slightly volatile

Change To Operating Activities

11.1 M

10.5 M

3.3 M

Slightly volatile

Total Cash From Financing Activities

58.3 M

55.5 M

16.2 M

Slightly volatile

End Period Cash Flow

18.5 M

25.7 M

9.5 M

Slightly volatile

Change To Netincome

16.7 M

15.9 M

5.2 M

Slightly volatile

Begin Period Cash Flow

17.5 M

21.7 M

7.9 M

Slightly volatile

Sale Purchase Of Stock

405.9 M

514 M

196.2 M

Slightly volatile

Change Receivables

146.4 K

164.7 K

179.8 K

Slightly volatile

Cash Flows Other Operating

2.4 M

2.7 M

2.9 M

Slightly volatile

Financial Ratios

Trends

Current Value

Last Year

Historical Average

10 Year Trend

Price To Sales Ratio

10.4

10.94

284

Slightly volatile

Days Sales Outstanding

32.14

30.61

18.6761

Slightly volatile

Average Payables

1.1 M

1.3 M

1.4 M

Slightly volatile

Stock Based Compensation To Revenue

1.14

1.2

16.2549

Slightly volatile

Capex To Depreciation

0.6

0.64

152

Slightly volatile

EV To Sales

10.12

10.65

205

Slightly volatile

Inventory Turnover

17.7

21.82

8.2973

Slightly volatile

Days Of Inventory On Hand

16.45

17.32

221

Slightly volatile

Payables Turnover

3.58

5.99

1.8684

Slightly volatile

Sales General And Administrative To Revenue

4.4 K

4.2 K

798

Slightly volatile

Research And Ddevelopement To Revenue

1.51

1.59

15.352

Slightly volatile

Capex To Revenue

0.16

0.17

1.3921

Slightly volatile

Cash Per Share

0.34

0.4

0.2209

Slightly volatile

Days Payables Outstanding

59.87

63.02

676

Slightly volatile

Income Quality

0.46

0.87

0.3649

Slightly volatile

Intangibles To Total Assets

0.0262

0.0276

0.0887

Slightly volatile

Current Ratio

0.91

0.96

1.1961

Slightly volatile

Receivables Turnover

17.87

9.66

8.4937

Slightly volatile

Capex Per Share

0.0107

0.0115

0.0067

Slightly volatile

Revenue Per Share

0.0813

0.0774

0.0282

Slightly volatile

Interest Debt Per Share

0.4

0.38

0.1089

Slightly volatile

Debt To Assets

0.35

0.62

0.1777

Slightly volatile

Operating Cycle

53.61

56.43

332

Slightly volatile

Days Of Payables Outstanding

59.87

63.02

676

Slightly volatile

Ebt Per Ebit

1.13

1.14

1.0423

Slightly volatile

Total Debt To Capitalization

0.55

0.72

0.252

Slightly volatile

Quick Ratio

0.9

0.95

1.1828

Slightly volatile

Cash Ratio

0.81

0.86

1.1004

Slightly volatile

Days Of Inventory Outstanding

16.45

17.32

221

Slightly volatile

Days Of Sales Outstanding

32.14

30.61

18.6761

Slightly volatile

Free Cash Flow Operating Cash Flow Ratio

1.12

1.17

1.0259

Slightly volatile

Fixed Asset Turnover

0.54

1.06

0.587

Slightly volatile

Debt Ratio

0.35

0.62

0.1777

Slightly volatile

Price Sales Ratio

10.4

10.94

284

Slightly volatile

Asset Turnover

0.13

0.1415

0.0355

Slightly volatile

Lucid Diagnostics Valuation Data

Trends

Current Value

Last Year

Historical Average

10 Year Trend

Market Cap

33.1 M

37.2 M

40.6 M

Slightly volatile

Enterprise Value

32.2 M

36.2 M

39.5 M

Slightly volatile

Lucid Fundamental Market Drivers

Lucid Upcoming Events

	12th of March 2024 Upcoming Quarterly Report	View
	20th of May 2024 Next Financial Report	View
	31st of December 2023 Next Fiscal Quarter End	View
	12th of March 2024 Next Fiscal Year End	View
	30th of September 2023 Last Quarter Report	View
	31st of December 2022 Last Financial Announcement	View

About Lucid Diagnostics Financial Statements

Lucid Diagnostics stakeholders use historical fundamental indicators, such as Lucid Diagnostics' revenue or net income, to determine how well the company is positioned to perform in the future. Although Lucid Diagnostics investors may analyze each financial statement separately, they are all interrelated. For example, changes in Lucid Diagnostics' assets and liabilities are reflected in the revenues and expenses on Lucid Diagnostics' income statement, which ultimately affect the company's gains or losses. Understanding these patterns can help in making the right long-term investment decisions in Lucid Diagnostics. Please read more on our technical analysis and fundamental analysis pages.

	Last Reported	Projected for Next Year
Current Deferred Revenue	842.4 K	748.8 K
Total Revenue	5 M	5.2 M
Cost Of Revenue	9.5 M	10 M
Stock Based Compensation To Revenue	1.20	1.14
Sales General And Administrative To Revenue	4.2 K	4.4 K
Research And Ddevelopement To Revenue	1.59	1.51
Capex To Revenue	0.17	0.16
Revenue Per Share	0.08	0.08
Ebit Per Revenue	(9.54)	(10.01)

Also Currently Popular

Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.

GOOG	Alphabet Inc Class C
V	Visa Class A
MSFT	Microsoft

When determining whether Lucid Diagnostics is a strong investment it is important to analyze Lucid Diagnostics' competitive position within its industry, examining market share, product or service uniqueness, and competitive advantages. Beyond financials and market position, potential investors should also consider broader economic conditions, industry trends, and any regulatory or geopolitical factors that may impact Lucid Diagnostics' future performance. For an informed investment choice regarding Lucid Stock, refer to the following important reports:

How To Invest In Lucid

Details

Is Lucid Stock a good investment?

Details

What is Lucid Diagnostics' Net Worth?

Details

Largest Health Care Equipment & Supplies Companies

View

Largest Health Care Equipment & Services Companies

View

Check out the analysis of Lucid Diagnostics Correlation against competitors.

For information on how to trade Lucid Stock refer to our How to Trade Lucid Stock guide.

You can also try the Price Transformation module to use Price Transformation models to analyze the depth of different equity instruments across global markets.

Is Health Care Equipment & Supplies space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Lucid Diagnostics. If investors know Lucid will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Lucid Diagnostics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.

Earnings Share

(0.77)

Revenue Per Share

0.053

Quarterly Revenue Growth

0.033

Return On Assets

(0.79)

Return On Equity

(3.31)

The market value of Lucid Diagnostics is measured differently than its book value, which is the value of Lucid that is recorded on the company's balance sheet. Investors also form their own opinion of Lucid Diagnostics' value that differs from its market value or its book value, called intrinsic value, which is Lucid Diagnostics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Lucid Diagnostics' market value can be influenced by many factors that don't directly affect Lucid Diagnostics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.

Please note, there is a significant difference between Lucid Diagnostics' value and its price as these two are different measures arrived at by different means. Investors typically determine if Lucid Diagnostics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Lucid Diagnostics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.

Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions

Feedback Blog

Made with optimal in San Francisco

2026 Macroaxis LLC

Lucid Financial Statements From 2010 to 2026

Lucid Diagnostics Total Revenue

5.25 Million

Lucid Diagnostics Balance Sheet

Lucid Diagnostics Income Statement

Lucid Diagnostics Cash Flow Statement

Financial Ratios

Lucid Diagnostics Valuation Data

Lucid Fundamental Market Drivers

Lucid Upcoming Events

About Lucid Diagnostics Financial Statements

Also Currently Popular

COMMON DESTINATIONS

MAIN CATEGORIES

COMPANY